argenx SE (Euronext & Nasdaq: ARGX), a global immunology company focused on improving the lives of people with severe autoimmune diseases, today announced its financial results for the first quarter…
Strong FY2024 Performance and Strategic Outlook for FY2025 The company reported core revenue growth of 7.4% at actual exchange rates (AER) and 2.8% at constant exchange rates (CER) for fiscal…
90% of Adults with Chronic Hepatitis Delta Who Cleared Virus on Bulevirtide Stayed Clear Nearly 2 Years After Stopping Treatment Gilead Sciences, Inc. (Nasdaq: GILD) today announced final results from…
Gilead Sciences, Inc. (Nasdaq: GILD) today announced new data from multiple analyses which reinforce that Livdelzi® (seladelpar), known as Lyvdelzi® in the European Union, is effective and generally well-tolerated for the treatment…
Enhertu Plus THP Shows Improved Safety and Efficacy Over Standard of Care in Early HER2-Positive Breast CancerAstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan), followed by a regimen of paclitaxel, trastuzumab,…
Novo Nordisk Reports Strong Operating Profit and Sales Growth, Updates 2025 Outlook Novo Nordisk announced a 22% increase in operating profit in Danish kroner, or 20% growth at constant exchange…
Roche (SIX: RO, ROG; OTCQX: RHHBY) has announced the launch of its Elecsys® PRO-C3 test, a new diagnostic tool developed in collaboration with Nordic Bioscience, to assess the severity of…
Global Health Inequities Slashing Lifespans by Decades, WHO Warns A new report by the World Health Organization (WHO) reveals that the root causes of poor health often lie outside the…
Teva and Alvotech Expand U.S. Biosimilar Portfolio with Approval for SELARSDI™ Teva Pharmaceuticals, the U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Alvotech (NASDAQ: ALVO) have…
WHO Highlights the Importance of Hand Hygiene Over Gloves on World Hand Hygiene Day Hand hygiene remains one of the most effective, affordable, and universal tools in preventing the spread…
73% of healthcare professionals (HCPs) report a disconnect between the availability of cutting-edge treatments and their effective implementation in clinical practice, while 3 in 4 oncologists say the rapid pace…
TREMFYA® Shows Sustained Long-Term Remission in Ulcerative Colitis Patients, According to Phase 3 QUASAR LTE Study More than 70% of patients in clinical remission and over 40% in endoscopic remission…